Thermo Fisher Scientific Inc. $TMO Shares Sold by Integral Investment Advisors Inc.

Integral Investment Advisors Inc. lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 35.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,300 shares of the medical research company’s stock after selling 1,281 shares during the period. Integral Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $933,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of TMO. CBIZ Investment Advisory Services LLC increased its holdings in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares during the last quarter. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter worth about $30,000. Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $31,000. DiNuzzo Private Wealth Inc. raised its position in shares of Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after acquiring an additional 61 shares in the last quarter. Finally, HighMark Wealth Management LLC boosted its holdings in Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 45 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday. Evercore ISI upped their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Leerink Partners lifted their target price on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Finally, Barclays lifted their price target on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Nineteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $595.75.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $564.49 on Tuesday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The stock’s 50-day moving average price is $505.57 and its 200 day moving average price is $454.34. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $213.16 billion, a PE ratio of 32.61, a price-to-earnings-growth ratio of 3.35 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same period last year, the business posted $5.28 EPS. The company’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,666 shares of company stock valued at $13,990,971 in the last 90 days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.